Slingshot Insights | Fprx Overview

FPRX Overview

Upcoming Projects (FPRX)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (FPRX)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (FPRX)

Phase 1b Initial data of FPA150 (ASCO 2019) in Solid tumors due at ASCO June 1 2019, 8am
Ticker: FPRX
Occurred on: Jun 01, 2019
Five Prime Therapeutics (FPRX) aims to complete Phase 1a/1b study of FPA008 in combination with Nivolumab in patients with selected advanced cancers in 2018
Ticker: FPRX
Occurred on: Jun 01, 2019
Five Prime Therapeutics (FPRX) to complete Phase 1 study of FPA144 in patients with Advanced Solid Tumors by early 2017
Ticker: FPRX
Occurred on: Dec 01, 2016
Five Prime Therapeutics (FPRX) to complete Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects in late 2016 to early 2017
Ticker: FPRX
Occurred on: Sep 14, 2016
Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA144 for the Treatment of Gastric Cancer
Ticker: FPRX
Occurred on: Jul 05, 2016
Phase 1b trial data of FP-1039 to be presented at American Society of Clinical Oncology (ASCO) 2016, if Arm C full data wil be positive, FPRX will seek to regain rights for FP-1039 in the U.S., Canada and the E.U. from GSK
Tickers: FPRX, GSK
Occurred on: Jun 20, 2016
5 arrested for alleged theft of trade secrets from GlaxoSmithKline (GSK) and Five Prime Therapeutics (FPRX), including data related to FP-1039
Tickers: GSK, FPRX
Occurred on: Jan 20, 2016

Strategic Initiatives (FPRX)

Amgen (AMGN) completes $1.9B acquisition of Five Prime Therapeutics (FPRX)
Tickers: AMGN, FPRX
Announcement Date: Apr 16, 2021